1982年毕业于兰州大学化学系，
1982年8月至1988年8月在美国耶鲁大学学习有机合成化学，获得博士学位；
1988年8月至2010年10月任职于默克制药公司加拿大研发中心，从事新药研发；
2010年11月创立了加拿大贝达药业，从事抗肿瘤小分子新药研发。
2012年4月获得南京市“321”人才计划支持，创立南京奥昭生物科技有限公司， 重点推进抗肿瘤靶向先导化合物的临床前研究工作。
2013年10月加入中国科学院上海有机所生物与化学交叉研究中心。

许多疾病还没有得到有效的的治疗，特别是癌症和神经退行性疾病的治疗依然是尚未攻克的难题，我们的药物化学将针对这些领域中已知的或新靶向寻找更为有效或全新的有效的治疗药物。目前我们的在研癌症靶向有ALK，cMet， BTK，HDAC6的抑制剂，同时也将探索新的抗体-小分子偶联抗癌药物合成化学。在治疗神经退行性疾病的新药研发方面，我们将和研究中心的生物学家紧密合作，对新的靶向先导化合物进行药物化学活性筛选和优化，共同探索治疗神经退行性疾病的有效药物。

(1) Wang, Z., Deschenes, D. "Enantiospecific synthesis via sequential diastereofacial and diastereotopic group selective reactions: enantiodivergent synthesis of syn-1,3-polyols." J. Am. Chem. Soc, 1992, 114, 1090-1091.
(2) Wang, Z., Warder, S., Perrier, H., Grimm, E. "A straightforward approach to the synthesis of the tricyclic core of taxanes." J. Org. Chem. 1993, 58, 2931-2932
(3) Prasit, P., Wang, Z., Brideau, C., Chan, C.-C., Charleson, S., Cromlish, W., Ethier, D., . Evans, J. F., Ford-Hutchinson, A. W., Gauthier, J. Y., Gordon, R., Guay, J., Gresser, M., S. Kargman, S., Kennedy, B., Leblanc, Y., Léger, S. , Mancini, J., O'Neill, G. P., Ouellet, M, Percival, D., Perrier, H., Riendeau, D., Rodger, I. W., Tagari, P. Thérien, M., Vickers, P., Wong, E., Xu, L.-J., Young, R. N. and Zamboni, R. "Rofecoxib, [MK 966, Vioxx‚, 4-( 4'-Methylsulfonylphenyl)-3- -2 Phenyl (5H)-Furanone]: the Discovery of a Selective and Orally Active Cyclooxygenase-2 Inhibitor." Bioorg. Med. Chem. Lett. 9, 1999,: 1773-78.
(4) Baskin,J.M. and Wang,Z. “A mild, convenient synthesis of sulfinates and sulfonamides from alkyl and aryl halides”. Tetrahedron Lett. 43 2002: 8479-8483.
(5) Baskin,J.M. and Wang,Z. “An Efficient Copper Catalyst for the Formation of Sulfones from Sulfinic Acid Salts and Aryl Iodides.” Organic Letters 4, 2002: 4423-4425.
(6) Beaulieu, C., Wang, Z., Denis, D., Greig, G.M., Lamontagne, S., Slipetz, D., O'Neill, G.P., and Wang, J. “Benzimidazoles as New Potent and Selective DP Antagonists for the treatment of Allergic Rhinitis”. Bioorg. Med. Chem. Lett. 14, 2004: 3195-3199.
(7) Beaulieu, C., Wang, Z., Guay, D., and Evans, D.A. “A mild and efficient new synthesis of aryl sulfones from boronic acids and sulfinic acid salts”. Tetrahedron Lett. 45, 2004: 3233-3236.
(8) Sturino,C.F., Lachance,N., Boyd,M.J., Berthelette,C., Li,L., Roy,B., Scheigetz,J., Tsou,N.N., Bateman,K.P., Day,S.H., Levesque,J.-F., Carrière,M.-C., Denis,D., Greig,G.M., Kargman,S.L., Lamontagne,S., Mathieu,M.-C., Sawyer,N., Slipetz,D., Jones,T.R., Nicoll-Griffith,D.A., Wang,Z., O'Neill,G.P., Zamboni,R.J., Metters,K.M., and Young,R.N. (2006). “Discovery of mk-0524, a potent and selective pgd2 receptor antagonist.” Journal of Medicinal Chemistry, 50, 2007, 794-806.
(9) Colucci, J.; Boyd, M.; Berthelette, C.; Chiasson, J.-F.; Wang, Z.; Ducharme, Y.; Friesen, R.; Wrona, M.; Levesque, J.-F.; Denis, D.; Mathieu, M.-C.; Stocco, R.; Therien, A. G..; Clarke, P.; Rowland, S.; Xu, D.; Han, Y. “Discovery of 4-{1-[({1-[4-(trifluoromethyl)benzyl]-1H-indol-7-yl}carbonyl)amino]cyclopropyl}benzoic acid (MF-766), a highly potent and selective EP4 antagonist for treating inflammatory painl.” Bioorganic & Medicinal Chemistry Letters (2010), 20(12), 3760-3763.
(10) Li, L.; Berthelette, C.; Chateauneuf, A.; Ouellet, M.; Sturino, C. F.; Wang, Z., “Potent and selective 5-LO inhibitor bearing benzothiophene pharmacophore: Discovery of MK-5286”, Bioorganic & Medicinal Chemistry Letters (2010), 20(24), 7440-7443.
(11) Gallant, M.; Beaulieu, C.; Berthelette, C.; Colucci, J.; Crackower, M. A..; Dalton, C.; Denis, D.; Ducharme, Y.; Friesen, R. W..; Guay, D.; Gervais, F. G.; Hamel, M.; Houle, R.; Krawczyk, C. M.; Kosjek, B.; Lau, S.; Leblanc, Y.; Lee, E. E.; Levesque, J.-F.; Mellon, C.; Molinaro, C.; Mullet, W.; O'Neill, G. P.; O'Shea, P.; Sawyer, N.; Sillaots, S.; Simard, D.; Slipetz, D.; Stocco, R.; Sorensen, D.; Truong, V. L.; Wong, E.; Wu, J.; Zaghdane, H.; Wang, Z., “Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases”, Bioorganic & Medicinal Chemistry Letters (2011), 21(1), 288-293.